Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +15

6,842 Shares in Moderna, Inc. $MRNA Purchased by Apollon Wealth ...

📈 Apollon Wealth Management LLC acquired a new stake of 6,842 shares valued at approximately $348,000 in the first quarter.

📉 President Stephen Hoge sold 53,336 shares worth roughly $2.74 million on June 15th under a pre-arranged trading plan.

💰 Moderna reported revenue of $389 million for the quarter, significantly beating the consensus estimate of $236.37 million.

📊 The company posted an EPS loss of $3.40 per share, missing analyst expectations of a smaller loss of $3.02.

🚀 Revenue increased by 260.2% compared to the same quarter last year, demonstrating strong top-line growth.

🏦 Institutional investors own 75.33% of the company's outstanding stock as of the latest filings.

📉 Insiders collectively sold over 125,000 shares valued at more than $6.19 million during the last quarter.

💸 The stock currently trades with a market capitalization of $32.46 billion and a negative P/E ratio of -10.04.

🛡️ Moderna maintains a robust balance sheet with a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

🔬 The company specializes in mRNA therapeutics, leveraging synthetic mRNA to produce proteins for disease prevention and treatment.

Bullish Signals
  • Moderna reported revenue of $389 million, which significantly exceeded the consensus estimate of $236.37 million.
  • Revenue grew by 260.2% year-over-year compared to the same quarter last year.
  • The company maintains a strong liquidity position with a current ratio of 2.41 and a quick ratio of 2.35.
  • Debt levels are minimal with a debt-to-equity ratio of only 0.08.
  • Institutional ownership remains high at 75.33%, indicating continued confidence from major investors.
Risk Factors
  • The company reported an EPS loss of $3.40 per share, missing the consensus estimate of a smaller loss of $3.02.
  • Analysts forecast a negative EPS of -6.51 for the current year, indicating continued unprofitability.
  • Significant insider selling occurred with President Stephen Hoge offloading 53,336 shares worth approximately $2.74 million.
  • Collective insider sales exceeded 125,000 shares valued at over $6.19 million during the last quarter.
Full Analysis
Apollon Wealth Management LLC purchased 6,842 shares of Moderna (MRNA) in the first quarter, valued at approximately $348,000. Other institutional investors including MUFG Securities EMEA plc and Flagship Harbor Advisors LLC also added new positions worth roughly $28,000 and $31,000 respectively in the second and fourth quarters. Smaller funds like Ameriflex Group Inc. and Cromwell Holdings LLC significantly increased their holdings by over 3,700% and 39.7% respectively, though their total share counts remain relatively low compared to major institutions. Insider trading activity saw significant sales from company leadership. Director Abbas Hussain sold 5,682 shares for approximately $264,951 in a pre-arranged Rule 10b5-1 plan on May 1st. President Stephen Hoge executed a larger sale of 53,336 shares worth about $2.74 million on June 15th under a similar trading plan. Collectively, insiders sold over 125,000 shares valued at more than $6.19 million during the last quarter, leaving them with 10.80% ownership of the company. Moderna reported its latest earnings on May 1st, posting revenue of $389 million which beat analyst estimates of $236.37 million by a wide margin, representing a 260.2% year-over-year increase. However, the company reported an EPS loss of $3.40 per share, missing the consensus estimate of a smaller loss of $3.02. The stock currently trades at a market cap of $32.46 billion with a price-to-earnings ratio of -10.04, reflecting its unprofitable status despite strong revenue growth. The article provides detailed financial metrics including a current ratio of 2.41 and a debt-to-equity ratio of 0.08, indicating a strong balance sheet with minimal debt. Analysts forecast an EPS of -6.51 for the current year. Moderna specializes in mRNA therapeutics and vaccines, with its flagship product being the COVID-19 vaccine which received full approval in multiple jurisdictions. The stock has seen significant volatility, trading between a one-year low of $22.28 and a high of $85.60.